National Health Investors (NHI) details CFO transition and pay terms
Rhea-AI Filing Summary
National Health Investors, Inc. announced a planned chief financial officer transition. John L. Spaid, Executive Vice President of Finance, Chief Financial Officer and Treasurer, will retire effective July 1, 2026, and his retirement is stated not to result from any disagreement with the company.
Todd Siefert, 52, will join as Executive Vice President Corporate Finance on June 1, 2026 and become Chief Financial Officer upon Mr. Spaid’s retirement. Siefert brings more than 25 years of corporate finance and capital markets experience, including senior roles at publicly traded REITs and responsibility for over $8.0 billion in capital markets transactions.
Siefert’s compensation includes a $500,000 annual base salary, a prorated 2026 cash incentive with a maximum of $490,000, and a prorated 2026 equity award with an aggregate target value of $437,500, split equally between time-based restricted stock and performance-based restricted stock units. He will also receive a $100,000 signing bonus and a one-time option grant for 50,000 shares vesting over two years.
A Transition Agreement and General Release with Mr. Spaid provides for vesting of certain restricted stock, continued vesting and exercisability of all outstanding options, medical premium payments through December 31, 2026 if elected, a prorated 2026 bonus, and a six-month non-compete and non-solicitation period following retirement.
Positive
- None.
Negative
- None.
Insights
Planned CFO succession with structured incentives and standard protections.
National Health Investors is implementing an orderly CFO handoff, with John Spaid retiring on July 1, 2026 and Todd Siefert stepping in after a one-month overlap. The company explicitly states Spaid’s retirement is not due to any disagreement, framing this as a normal succession.
Siefert’s package—$500,000 base salary, up to $490,000 2026 cash incentive, and a $437,500 equity target split between time-based and performance-based awards—aligns a large portion of pay with performance. The grant of options over 50,000 shares further ties compensation to equity value.
The Transition Agreement offers Spaid partial accelerated vesting, continued option vesting, medical premiums through December 31, 2026, and a six‑month non‑compete and non‑solicitation. These terms resemble typical senior executive retirement arrangements, suggesting continuity rather than distress, though the real impact on strategy will emerge through future disclosures.
8-K Event Classification
Key Figures
Key Terms
Transition Agreement and General Release regulatory
restricted stock awards financial
performance-based restricted stock units financial
indemnification agreement regulatory
non-compete regulatory
non-solicitation regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.